Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a top 20 pharmaceutical company for an international study on type 2 diabetes. The study explores an investigational drug’s effectiveness for maintaining glycemic control for individuals newly diagnosed with type 2 diabetes.
There are currently an estimated 171 million individuals worldwide with a diagnosis of type 2 diabetes and that number is expected to grow. These statistics only highlight the need for new compounds and forms of treatment for type 2 diabetes and explains why metabolic disorders fall within the top 5 therapeutic areas currently of being studied.
“Praxis’ historical successes in recruiting for type 2 diabetes made the opportunity to be a part of this study even more exciting,” said Praxis President and CEO, David Fox. “With so many competing treatment options for individuals with type 2 diabetes, a well thought out and strategic recruitment effort was clearly needed to ensure a timely enrollment. We look forward to seeing this trial through to success.”
A full compliment of marketing and communications tools will be implemented in the U.S. and five other participating countries, based on strategic predictive modeling data from PraxisDirect, Praxis’ real-time study management software.